NCBiotech News

The Angel Capital Association (ACA), the world’s largest association of angel investors, has honored Winston-Salem-based BMI OrganBank with its 2026 Luis Villalobos Awards in the life sciences category.

Novartis will add a new North Carolina facility for active pharmaceutical ingredient (API) manufacturing for solid dosage tablets, capsules and RNA therapeutics to its campus in Morrisville. 

Ask Randall Johnson what makes the Southeastern North Carolina bioeconomy special, and he doesn't hesitate. "The region is rich with assets," he said, a phrase that barely scratches the surface of what's happening across the Cape Fear corridor.

UNC Charlotte’s second annual Invention of the Year Awards Gala celebrated outstanding faculty and student inventors on April 23 at The Dubois Center at UNC Charlotte Center City.

North Carolina is in an unprecedented period of reinvestment for its biomanufacturing workforce training. Community colleges across the state have been making investments exceeding $230 million over the past few years. This commitment to new and expanded life sciences training programs and facilities builds on the state's history and strength in workforce development.

It has been known for years by insiders as the “hidden gem” of North Carolina’s life sciences ecosystem. And now, after four decades of unique and valuable service to partners statewide, the North Carolina Biotechnology Center’s (NCBiotech’s) Life Sciences Intelligence (LSI) unit is now a “gem on display.” 

Central Carolina Community College (CCCC) is transforming a former Magneti Marelli auto manufacturing site in Sanford into the E. Eugene Moore Manufacturing and Biotech Solutions Center, a regional hub for technical training across Chatham, Harnett and Lee counties. The facility, which ended operations in 2021, now represents a second act for both the space and the community it serves.

AbbVie today announced a $1.4 billion investment to build a new drug production facility on a 185-acre campus in Durham County, where the company expects to employ 734 people. 

The company’s state-of-the-art facility at this new campus in Durham County, near Research Triangle Park, will have production and manufacturing operations for its current and future medicines in the areas of immunology, oncology and neuroscience. 

A conversation on the future of artificial intelligence in life sciences and healthcare, featuring keynote speakers Brian Caveney, M.D., J.D., chief medical and scientific officer at Labcorp, and Angela A. Shippy, M.D., MHA, FACP, FHM, senior physician executive and clinical innovation lead for healthcare and life sciences at Amazon Web Services, will anchor Triad BioNight 2026, scheduled for May 27 in Greensboro.

With roots in the research labs at North Carolina State University, ChromaGenix has opened a new $35 million, 6,500-square-foot research and development and manufacturing facility at NC State’s Centennial Campus.

NCBioImpact, a public/private partnership created to bring together key resources to produce world-class biopharma manufacturing training programs, organized a unique event to enhance communication and information-sharing around workforce training and development.

Incyclix Bio, LLC, a cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today announced that it has raised $5 million in additional funds for its Series B financing from new investor Hatteras Venture Partners.

About 2 million Americans have a heart condition called “paroxysmal supraventricular tachycardia,” or PSVT. An electrical problem in the heart causes it to beat very fast—150-220 beats per minute—versus the normal 60-100 beats.

United Therapeutics, a public benefit corporation with co-headquarters in Research Triangle Park, is poised to expand the use of its drug Tyvaso for treating a serious lung disease following positive clinical trial results.

North Carolina’s reputation as a leading state for life sciences is well-known, both in the United States and globally.

But there’s no guarantee that will always be the case. Pharmaceutical and biotechnology leaders, working in conjunction with others who are a part of the state’s life sciences ecosystem, can’t sit still while the rest of the world catches up, speakers at a recent conference in Raleigh emphasized.